These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 8670046)

  • 41. Molecular mechanism of activation and superactivation of Ret tyrosine kinases by ultraviolet light irradiation.
    Kato M; Iwashita T; Akhand AA; Liu W; Takeda K; Takeuchi K; Yoshihara M; Hossain K; Wu J; Du J; Oh C; Kawamoto Y; Suzuki H; Takahashi M; Nakashima I
    Antioxid Redox Signal; 2000; 2(4):841-9. PubMed ID: 11213488
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease.
    Angrist M; Bolk S; Thiel B; Puffenberger EG; Hofstra RM; Buys CH; Cass DT; Chakravarti A
    Hum Mol Genet; 1995 May; 4(5):821-30. PubMed ID: 7633441
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome.
    Ponder BA
    Cancer Res; 1999 Apr; 59(7 Suppl):1736s-1741s; discussion 1742s. PubMed ID: 10197589
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2.
    Ponder BA
    Cancer Surv; 1995; 25():195-205. PubMed ID: 8718519
    [No Abstract]   [Full Text] [Related]  

  • 46. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease.
    Eng C; Mulligan LM
    Hum Mutat; 1997; 9(2):97-109. PubMed ID: 9067749
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutations of the RET proto-oncogene in Hirschsprung's disease.
    Edery P; Lyonnet S; Mulligan LM; Pelet A; Dow E; Abel L; Holder S; Nihoul-Fékété C; Ponder BA; Munnich A
    Nature; 1994 Jan; 367(6461):378-80. PubMed ID: 8114939
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck.
    Bocciardi R; Mograbi B; Pasini B; Borrello MG; Pierotti MA; Bourget I; Fischer S; Romeo G; Rossi B
    Oncogene; 1997 Nov; 15(19):2257-65. PubMed ID: 9393871
    [TBL] [Abstract][Full Text] [Related]  

  • 49. RET in human development and oncogenesis.
    Edery P; Eng C; Munnich A; Lyonnet S
    Bioessays; 1997 May; 19(5):389-95. PubMed ID: 9174404
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differential effects of leukocyte common antigen-related protein on biochemical and biological activities of RET-MEN2A and RET-MEN2B mutant proteins.
    Qiao S; Iwashita T; Furukawa T; Yamamoto M; Sobue G; Takahashi M
    J Biol Chem; 2001 Mar; 276(12):9460-7. PubMed ID: 11121408
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.
    Melillo RM; Santoro M; Ong SH; Billaud M; Fusco A; Hadari YR; Schlessinger J; Lax I
    Mol Cell Biol; 2001 Jul; 21(13):4177-87. PubMed ID: 11390647
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
    Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
    J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ligand stimulation of a Ret chimeric receptor carrying the activating mutation responsible for the multiple endocrine neoplasia type 2B.
    Rizzo C; Califano D; Colucci-D'Amato GL; De Vita G; D'Alessio A; Dathan NA; Fusco A; Monaco C; Santelli G; Vecchio G; Santoro M; de Franciscis V
    J Biol Chem; 1996 Nov; 271(46):29497-501. PubMed ID: 8910618
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
    Kambouris M; Jackson CE; Feldman GL
    Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multiple endocrine neoplasia type 2: recent progress in diagnosis and management.
    Heshmati HM; Hofbauer LC
    Eur J Endocrinol; 1997 Dec; 137(6):572-8. PubMed ID: 9437218
    [No Abstract]   [Full Text] [Related]  

  • 56. The physical map of the human RET proto-oncogene.
    Pasini B; Hofstra RM; Yin L; Bocciardi R; Santamaria G; Grootscholten PM; Ceccherini I; Patrone G; Priolo M; Buys CH
    Oncogene; 1995 Nov; 11(9):1737-43. PubMed ID: 7478601
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
    Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M
    Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The RET proto-oncogene: a challenge to our understanding of disease pathogenesis.
    Kusafuka T; Puri P
    Pediatr Surg Int; 1997; 12(1):11-8. PubMed ID: 9035202
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations.
    Iwashita T; Murakami H; Kurokawa K; Kawai K; Miyauchi A; Futami H; Qiao S; Ichihara M; Takahashi M
    Biochem Biophys Res Commun; 2000 Feb; 268(3):804-8. PubMed ID: 10679286
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Mutations of RET proto-oncogene in Hirschsprung disease].
    Lyonnet S; Edery P; Mulligan LM; Pelet A; Dow E; Abel L; Holder S; Nihoul-Fékéte C; Ponder BA; Munnich A
    C R Acad Sci III; 1994 Apr; 317(4):358-62. PubMed ID: 8000915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.